Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Two single-center, open-label studies examined the potential effects of tiagabine on the pharmacokinetics and safety of carbamazepine and phenytoin at steady state. Twelve adult patients with seizures controlled by an individualized fixed dosage of antiepilepsy medication (carbamazepine or phenytoin) participated in each study. On day 1, the pharmacokinetics of the baseline antiepilepsy drug were determined. On days 2 through 18, tiagabine was titrated from 8 to 48 mg/d (or the maximum tolerated dose up to 48 mg/d), and the usual fixed dosage of carbamazepine or phenytoin was continued. The pharmacokinetic assessment was repeated on day 18. There were no statistically significant differences in carbamazepine, carbamazepine epoxide, and phenytoin pharmacokinetic parameters when either drug was administered alone or in combination with tiagabine. In each study, 11 of 12 patients (92%) experienced treatment-emergent adverse events after tiagabine was added. The most frequent adverse events were dizziness, headache, difficulty concentrating, drowsiness, and tremor. Most symptoms were mild or moderate in severity and resolved without further treatment, although tiagabine dosage reductions were required by 4 patients in the carbamazepine study and by 3 patients in the phenytoin study. There were no clinically important effects on physical examination or neurologic test results, laboratory values, or vital signs. The results suggest that addition of tiagabine to a fixed regimen of either carbamazepine or phenytoin is generally well tolerated and that carbamazepine and phenytoin steady-state pharmacokinetics are unaffected by the addition of tiagabine.
Gustavson
L E
LE
Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Cato
A
A
Boellner
S W
SW
Cao
G X
GX
Qian
J X
JX
Guenther
H J
HJ
Sommerville
K W
KW
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000097:blood / Q000493:pharmacokinetics*; D004244:Dizziness / Q000139:chemically induced; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D018755:GABA Agonists / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009557:Nipecotic Acids / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D010672:Phenytoin / Q000097:blood / Q000493:pharmacokinetics*; D012640:Seizures / Q000097:blood / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D000078308:Tiagabine; D014202:Tremor / Q000139:chemically induced
D000927:Anticonvulsants; D018755:GABA Agonists; D009557:Nipecotic Acids; D002220:Carbamazepine; D010672:Phenytoin; D000078308:Tiagabine